Why Was Delcath Systems Stock Down on Aug 6, 2026?

Delcath Systems shares are trading lower today, giving back part of an earlier gain that followed this morning's second-quarter 2026 report. The company, which makes the HEPZATO liver-directed chemotherapy delivery system, reported earnings of $0.07 per share against an estimate of a $0.09 loss — a swing from an expected loss to an actual profit — on revenue of $29.13 million versus $26.26 million expected. HEPZATO procedure volume grew approximately 30% year over year, and the company raised full-year 2026 revenue guidance to $104 million-$108 million.

Today's pullback comes despite that underlying strength, which is not unusual for a small-cap stock that moved sharply on the initial release — some of the earlier gain reflects normal profit-taking rather than any change in the fundamentals reported this morning. The company also disclosed early retrospective data presented at the ESMO Breast Cancer 2026 conference showing a 60% hepatic partial response rate using its perfusion technique in metastatic breast cancer, a use case beyond its primary approved indication. For the full breakdown, see our dated report on the earnings and the data.